News >

FDA Approves First-Line Panitumumab for RAS Wild-Type mCRC

Silas Inman @silasinman
Published: Friday, Jun 30, 2017

Dr. Marwan G. Fakih

Marwan G. Fakih, MD

The FDA has approved panitumumab (Vectibix) in combination with FOLFOX as a frontline treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC), according to Amgen, the company marketing the anti-EGFR antibody.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x